Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash from Operations (2016 - 2025)

United Therapeutics (UTHR) has disclosed Cash from Operations for 17 consecutive years, with 346200000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 1.47% to 346200000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1561200000.0 through Dec 2025, up 17.64% year-over-year, with the annual reading at 1561200000.0 for FY2025, 17.64% up from the prior year.
  • Cash from Operations hit 346200000.0 in Q4 2025 for United Therapeutics, down from 562100000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 562100000.0 in Q3 2025 to a low of 89800000.0 in Q1 2021.
  • Historically, Cash from Operations has averaged 263350000.0 across 5 years, with a median of 245400000.0 in 2022.
  • Biggest five-year swings in Cash from Operations: crashed 58.15% in 2021 and later surged 221.49% in 2022.
  • Year by year, Cash from Operations stood at 174600000.0 in 2021, then dropped by 26.58% to 128200000.0 in 2022, then increased by 17.55% to 150700000.0 in 2023, then surged by 126.41% to 341200000.0 in 2024, then grew by 1.47% to 346200000.0 in 2025.
  • Business Quant data shows Cash from Operations for UTHR at 346200000.0 in Q4 2025, 562100000.0 in Q3 2025, and 191700000.0 in Q2 2025.